PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives

Author(s): Thomas Gevaert*, Alessia Cimadamore, Rodolfo Montironi, Markus Eckstein

Journal Name: Current Drug Targets

Volume 22 , Issue 2 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.

Keywords: PD-L1, immunohistochemistry, urothelial carcinoma, biomarker, interchangeability, immunotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 09 May, 2020
Page: [162 - 170]
Pages: 9
DOI: 10.2174/1389450121666200510015216
Price: $65

Article Metrics

PDF: 40